M&R Capital Management’s AbbVie ABBV Stock Holding History

M&R Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$3.25M	Buy	16,447 +1,149	+8%	+$214K	0.72%	36
2024 Q2	$2.62M	Sell	15,298 -327	-2%	-$54.2K	0.63%	35
2024 Q1	$2.84M	Sell	15,625 -94	-0.6%	-$16.2K	0.7%	36
2023 Q4	$2.44M	Sell	15,719 -864	-5%	-$126K	0.61%	34
2023 Q3	$2.47M	Sell	16,583 -289	-2%	-$42.4K	0.68%	33
2023 Q2	$2.27M	Sell	16,872 -2,394	-12%	-$351K	0.59%	35
2023 Q1	$3.07M	Buy	19,266 +3,139	+19%	+$480K	0.86%	30
2022 Q4	$2.61M	Sell	16,127 -413	-2%	-$63.3K	0.72%	37
2022 Q3	$2.22M	Buy	16,540 +13	+0.1%	+$1.86K	0.63%	41
2022 Q2	$2.53M	Buy	16,527 +1,756	+12%	+$268K	0.66%	38
2022 Q1	$2.4M	Buy	14,771 +1,591	+12%	+$231K	0.51%	42
2021 Q4	$1.78M	Sell	13,180 -1,393	-10%	-$165K	0.37%	52
2021 Q3	$1.57M	Buy	14,573 +206	+1%	+$23.5K	0.36%	53
2021 Q2	$1.62M	Buy	14,367 +206	+1%	+$23.2K	0.37%	53
2021 Q1	$1.53M	Sell	14,161 -1,488	-10%	-$159K	0.38%	52
2020 Q4	$1.68M	Sell	15,649 -189	-1%	-$18.2K	0.38%	49
2020 Q3	$1.39M	Sell	15,838 -34	-0.2%	-$3.2K	0.34%	53
2020 Q2	$1.56M	Sell	15,872 -1,472	-8%	-$130K	0.42%	50
2020 Q1	$1.32M	Hold	17,344	–	–	0.39%	54
2019 Q4	$1.53M	Sell	17,344 -627	-3%	-$52.1K	0.34%	62
2019 Q3	$1.36M	Sell	17,971 -1,493	-8%	-$102K	0.32%	74
2019 Q2	$1.42M	Hold	19,464	–	–	0.32%	74
2019 Q1	$1.55M	Sell	19,464 -100	-0.5%	-$8.18K	0.35%	62
2018 Q4	$1.8M	Sell	19,564 -6,523	-25%	-$574K	0.47%	55
2018 Q3	$2.47M	Sell	26,087 -87	-0.3%	-$8.25K	0.54%	50
2018 Q2	$2.42M	Sell	26,174 -884	-3%	-$86.3K	0.56%	49
2018 Q1	$2.56M	Buy	27,058 +665	+3%	+$73.1K	0.59%	47
2017 Q4	$2.55M	Sell	26,393 -356	-1%	-$33.6K	0.59%	45
2017 Q3	$2.38M	Sell	26,749 -1,392	-5%	-$106K	0.57%	48
2017 Q2	$1.99M	Sell	28,141 -111	-0.4%	-$7.46K	0.49%	51
2017 Q1	$1.84M	Sell	28,252 -467	-2%	-$29.4K	0.46%	53
2016 Q4	$1.8M	Sell	28,719 -1,369	-5%	-$83.6K	0.49%	53
2016 Q3	$1.9M	Sell	30,088 -679	-2%	-$44K	0.54%	51
2016 Q2	$1.9M	Buy	30,767 +2,178	+8%	+$133K	0.56%	50
2016 Q1	$1.63M	Sell	28,589 -305	-1%	-$17K	0.49%	52
2015 Q4	$1.71M	Buy	28,894 +2,620	+10%	+$151K	0.49%	51
2015 Q3	$1.43M	Buy	26,274 +330	+1%	+$21.5K	0.39%	58
2015 Q2	$1.74M	Sell	25,944 -1,770	-6%	-$116K	0.41%	58
2015 Q1	$1.62M	Buy	27,714 +1,750	+7%	+$106K	0.38%	58
2014 Q4	$1.7M	Buy	25,964 +1,800	+7%	+$113K	0.4%	59
2014 Q3	$1.4M	Sell	24,164 -75	-0.3%	-$4.16K	0.33%	63
2014 Q2	$1.37M	Sell	24,239 -25	-0.1%	-$1.31K	0.32%	66
2014 Q1	$1.25M	Sell	24,264 -525	-2%	-$26.5K	0.3%	67
2013 Q4	$1.31K	Sell	24,789 -325	-1%	-$16K	0.34%	63
2013 Q3	$1.12M	Sell	25,114 -1,100	-4%	-$48.8K	0.32%	63
2013 Q2	$1.08M	Buy	+26,214	New	+$1.15M	0.31%	67

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

M&R Capital Management's ABBV Position: Q3 2024 in Review

M&R Capital Management increased its AbbVie (ABBV) stake by 7.5% in Q3 2024, buying an estimated $214K and bringing the position to 16,447 shares worth $3.25M. The position accounts for 0.72% of the portfolio, ranked #36.

M&R Capital Management first reported a position in ABBV in Q2 2013 and has held it in 46 quarters since. 3,499 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

M&R Capital Management held 16,447 shares of AbbVie worth $3.25M as of Q3 2024.
M&R Capital Management bought 1,149 AbbVie shares in Q3 2024, an estimated $214K.
AbbVie made up 0.72% of M&R Capital Management's portfolio in Q3 2024, its #36 holding.
M&R Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 46 quarters since.
3,499 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on M&R Capital Management's 13F filing for Q3 2024, filed 2 Oct 2024.